Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CD33 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | P20138 |
| Other Accession | NP_001763, 945 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | 39825 Da |
| Application Notes | CD33 antibody can be used for detection of CD33 by Western blot at 1 - 2 μg/mL. |
| Gene ID | 945 |
|---|---|
| Target/Specificity | CD33 antibody was raised against a 14 amino acid synthetic peptide near the center of human CD33. The immunogen is located within amino acids 180 - 230 of CD33. |
| Reconstitution & Storage | CD33 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | CD33 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CD33 |
|---|---|
| Synonyms | SIGLEC3 |
| Function | Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:11320212, PubMed:15597323). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:10887109, PubMed:28325905). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP- 2 (PubMed:10206955, PubMed:10556798, PubMed:10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955, PubMed:10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323). |
| Cellular Location | [Isoform CD33M]: Cell membrane; Single-pass type I membrane protein |
| Tissue Location | Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CD33 Antibody: CD33 is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family that is highly expressed on myeloid progenitor cells. Assessment of CD33 expression is of great importance in the immunodiagnosis of acute leukemia, allowing distinction between myeloid and lymphoid origin, as CD33 is generally restricted to the myelomonocytic lineage. CD33 can associate with the protein-tyrosine phosphatases SHP-1 and SHP-2 and thus could modulate downstream signaling events associated with cell activation. Common variants of CD33 have been found to be associated with late-onset Alzheimer's disease.
References
Freeman SD, Kelm S, Barber EK, et al. Characterization of CD33 as a new member of the sialoadhesion family of cellular interaction molecules. Blood 1995; 85:2005-12.
Crocker PR and Varki A. Siglecs, sialic acids, and innate immunity. Trends Immunol. 2001; 22:337-42.
Taylor VC, Buckley CD, Douglass M, et al. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. 1999; 274:11505-12
Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA are associated with late-onset Alzheimer’s disease. Nat. Genet. 2011; 43:436-41
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
